A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4

British Journal of Clinical Pharmacology

Volumn 74, Issue 5, 2012, Pages 873-885

  Gaohua, Lu ^a   Abduljalil, Khaled ^a   Jamei, Masoud ^a   Johnson, Trevor N ^a   Rostami Hodjegan, Amin ^a,b  

^a CERTARA UK LIMITED   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Caffeine; Metoprolol; Midazolam; Physiologically based pharmacokinetic model; Pregnancy

Indexed keywords

CAFFEINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; METOPROLOL; MIDAZOLAM;

ADIPOSE TISSUE; ARTICLE; BONE; BONE LEVEL; BRAIN LEVEL; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG METABOLISM; DRUG TISSUE LEVEL; ENZYME ACTIVITY; FEMALE; GASTROINTESTINAL TRACT; HUMAN; KIDNEY; LIVER; LUNG; MODEL; MUSCLE; PHARMACOLOGICAL PARAMETERS; PREGNANCY; PREGNANCY PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL; PRIORITY JOURNAL; SKIN; SPLEEN;

ADULT; CAFFEINE; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; DRUG DESIGN; FEMALE; HUMANS; METOPROLOL; MIDAZOLAM; MODELS, BIOLOGICAL; PREGNANCY; PREGNANCY TRIMESTER, THIRD; YOUNG ADULT;

EID: 84867348647     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2012.04363.x     Document Type: Article

References (51)

1. Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet 2005; 44: 989-1008.
2. Hodge LS, Tracy TS. Alterations in drug disposition during pregnancy: implications for drug therapy. Expert Opin Drug Metab Toxicol 2007; 3: 557-571.
3. Abduljalil K, Furness P, Johnson TN, Rostami-Hodjegan A, Soltani H. Physiological, anatomical and metabolic changes with gestational age during normal pregnancy: creating a database and analysing trends for parameters required in physiologically based pharmacokinetic modelling. Clin Pharmacokinet 2012; 51: 365-396.
4. Rodger MA, Makropoulos D, Walker M, Keely E, Karovitch A, Wells PS. Participation of pregnant women in clinical trials: will they participate and why? Am J Perinatol 2003; 20: 69-76.
5. McCullough LB, Coverdale JH, Chervenak FA. A comprehensive ethical framework for responsibly designing and conducting pharmacologic research that involves pregnant women. Am J Obstet Gynecol 2005; 193: 901-907.
6. Chambers CD, Polifka JE, Friedman JM. Drug safety in pregnant women and their babies: ignorance not bliss. Clin Pharmacol Ther 2008; 83: 181-183.
7. Herring C, McManus A, Weeks A. Off-label prescribing during pregnancy in the UK: an analysis of 18, 000 prescriptions in Liverpool Women's Hospital. Int J Pharm Pract 2010; 18: 226-229.
8. Rayburn WF, Turnbull GL. Off-label drug prescribing on a state university obstetric service. J Reprod Med 1995; 40: 186-188.
9. Mattison D, Zajicek A. Gaps in knowledge in treating pregnant women. Gend Med 2006; 3: 169-182.
10. Freeman MP, Nolan PE Jr, Davis MF, Anthony M, Fried K, Fankhauser M, Woosley RL, Moreno F. Pharmacokinetics of sertraline across pregnancy and postpartum. J Clin Psychopharmacol 2008; 28: 646-653.
11. Hostetter A, Stowe ZN, Strader JR Jr, McLaughlin E, Llewellyn A. Dose of selective serotonin uptake inhibitors across pregnancy: clinical implications. Depress Anxiety 2000; 11: 51-57.
12. Sit DK, Perel JM, Helsel JC, Wisner KL. Changes in antidepressant metabolism and dosing across pregnancy and early postpartum. J Clin Psychiatry 2008; 69: 652-658.
13. Center for Drug Evaluation Research. Guidance for Industry: Establishing Pregnancy Exposure Registries. Rockville: Food and Drug Administration, US Department of Health and Human Services, 2002; 1-24. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071639.pdf (last accessed March 2012).
14. Center for Drug Evaluation Research. Guidance for Industry, Pharmacokinetics in Pregnancy - Study Design, Data Analysis, and Impact on Dosing and Labeling. Rockville: Food and Drug Administration, US Department of Health and Human Services, 2004; 1-14. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072133.pdf (last accessed March 2012).
15. Committee for Medicinal Products for Human Use. Guideline on the Exposure to Medicinal Products during Pregnancy: Need for Post-Authorisation Data. London: European Medicines Agency, 2005; 1-21. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/11/WC500011303.pdf (last accessed March 2012).
16. Gaohua L, Abduljalil K, Jamei M, Johnson TN, Soltani H, Rostami-Hodjegan A. Physiologically-based pharmacokinetic (PBPK) models for assessing the kinetics of xenobiotics during pregnancy: achievements and shortcomings. Curr Drug Metab 2012; 13: 695-720.
17. Luecke RH, Wosilait WD, Pearce BA, Young JF. A computer model and program for xenobiotic disposition during pregnancy. Comput Methods Programs Biomed 1997; 53: 201-224.
18. Clewell HJ, Gearhart JM, Gentry PR, Covington TR, VanLandingham CB, Crump KS, Shipp AM. Evaluation of the uncertainty in an oral reference dose for methylmercury due to interindividual variability in pharmacokinetics. Risk Anal 1999; 19: 547-558.
19. Corley RA, Mast TJ, Carney EW, Rogers JM, Daston GP. Evaluation of physiologically based models of pregnancy and lactation for their application in children's health risk assessments. Crit Rev Toxicol 2003; 33: 137-211.
20. Andrew MA, Hebert MF, Vicini P. Physiologically based pharmacokinetic model of midazolam disposition during pregnancy. Conf Proc IEEE Eng Med Biol Soc 2008; 2008: 5454-5457.
21. Pilari S, Preusse C, Huisinga W. Gestational influences on the pharmacokinetics of gestagenic drugs: a combined in silico, in vitro and in vivo analysis. Eur J Pharm Sci 2011; 42: 318-331.
22. Jamei M, Marciniak S, Feng K, Barnett A, Tucker GT, Rostami-Hodjegan A. The Simcyp® Population-Based ADME Simulator. Expert Opin Drug Metab Toxicol 2009; 5: 211-223.
23. Luecke RH, Wosilait WD, Young JF. Mathematical modeling of human embryonic and fetal growth rates. Growth Dev Aging 1999; 63: 49-59.
24. Brazier JL, Ritter J, Berland M, Khenfer D, Faucon G. Pharmacokinetics of caffeine during and after pregnancy. Dev Pharmacol Ther 1983; 6: 315-322.
25. Aldridge A, Bailey J, Neims AH. The disposition of caffeine during and after pregnancy. Semin Perinatol 1981; 5: 310-314.
26. Knutti R, Rothweiler H, Schlatter C. Effect of pregnancy on the pharmacokinetics of caffeine. Eur J Clin Pharmacol 1981; 21: 121-126.
27. Parsons WD, Pelletier JG. Delayed elimination of caffeine by women in the last 2 weeks of pregnancy. Can Med Assoc J 1982; 127: 377-380.
28. Hogstedt S, Lindberg B, Peng DR, Regardh CG, Rane A. Pregnancy-induced increase in metoprolol metabolism. Clin Pharmacol Ther 1985; 37: 688-692.
29. Hebert MF, Easterling TR, Kirby B, Carr DB, Buchanan ML, Rutherford T, Thummel KE, Fishbein DP, Unadkat JD. Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study. Clin Pharmacol Ther 2008; 84: 248-253.
30. Rostami-Hodjegan A, Tucker GT. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 2007; 6: 140-148.
31. Rodgers T, Leahy D, Rowland M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci 2005; 94: 1259-1276.
32. Rodgers T, Rowland M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 2006; 95: 1238-1257.
33. Luecke RH, Wosilait WD, Pearce BA, Young JF. A physiologically based pharmacokinetic computer model for human pregnancy. Teratology 1994; 49: 90-103.
34. Luecke RH, Wosilait WD, Young JF. Mathematical analysis for teratogenic sensitivity. Teratology 1997; 55: 373-380.
35. Young JF, Branham WS, Sheehan DM, Baker ME, Wosilait WD, Luecke RH. Physiological 'constants' for PBPK models for pregnancy. J Toxicol Environ Health 1997; 52: 385-401.
36. Young JF. Physiologically-based pharmacokinetic model for pregnancy as a tool for investigation of developmental mechanisms. Comput Biol Med 1998; 28: 359-364.
37. Andrew MA, Hebert MF, Vicini P. Physiologically Based Pharmacokinetic (PBPK) modeling of midazolam disposition in pregnant and postpartum women. Abstract 1760. Berlin: Population Approach Group in Europe, Nineteenth Meeting, 8-11 June 2010. Available at http://www.page-meeting.org/?abstract=1760 (last accessed March 2012).
38. Tsutsumi K, Kotegawa T, Matsuki S, Tanaka Y, Ishii Y, Kodama Y, Kuranari M, Miyakawa I, Nakano S. The effect of pregnancy on cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activities in humans. Clin Pharmacol Ther 2001; 70: 121-125.
39. Tracy TS, Venkataramanan R, Glover DD, Caritis SN. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy. Am J Obstet Gynecol 2005; 192: 633-639.
40. Wadelius M, Darj E, Frenne G, Rane A. Induction of CYP2D6 in pregnancy. Clin Pharmacol Ther 1997; 62: 400-407.
41. Laurent-Kenesi MA, Funck-Brentano C, Poirier JM, Decolin D, Jaillon P. Influence of CYP2D6-dependent metabolism on the steady-state pharmacokinetics and pharmacodynamics of metoprolol and nicardipine, alone and in combination. Br J Clin Pharmacol 1993; 36: 531-538.
42. Kaila N, Straka RJ, Brundage RC. Mixture models and subpopulation classification: a pharmacokinetic simulation study and application to metoprolol CYP2D6 phenotype. J Pharmacokinet Pharmacodyn 2007; 34: 141-156.
43. Syme MR, Paxton JW, Keelan JA. Drug transfer and metabolism by the human placenta. Clin Pharmacokinet 2004; 43: 487-514.
44. Myllynen P, Immonen E, Kummu M, Vahakangas K. Developmental expression of drug metabolizing enzymes and transporter proteins in human placenta and fetal tissues. Expert Opin Drug Metab Toxicol 2009; 5: 1483-1499.
45. Vahakangas K, Myllynen P. Drug transporters in the human blood-placental barrier. Br J Pharmacol 2009; 158: 665-678.
46. Prat A, Biernacki K, Wosik K, Antel JP. Glial cell influence on the human blood-brain barrier. Glia 2001; 36: 145-155.
47. de Boer AG, van der Sandt IC, Gaillard PJ. The role of drug transporters at the blood-brain barrier. Annu Rev Pharmacol Toxicol 2003; 43: 629-656.
48. Virgintino D, Errede M, Girolamo F, Capobianco C, Robertson D, Vimercati A, Serio G, Di Benedetto A, Yonekawa Y, Frei K, Roncali L. Fetal blood-brain barrier P-glycoprotein contributes to brain protection during human development. J Neuropathol Exp Neurol 2008; 67: 50-61.
49. Dutheil F, Dauchy S, Diry M, Sazdovitch V, Cloarec O, Mellottee L, Bieche I, Ingelman-Sundberg M, Flinois JP, de Waziers I, Beaune P, Decleves X, Duyckaerts C, Loriot MA. Xenobiotic-metabolizing enzymes and transporters in the normal human brain: regional and cellular mapping as a basis for putative roles in cerebral function. Drug Metab Dispos 2009; 37: 1528-1538.
50. Ambrosi G, Virgintino D, Benagiano V, Maiorano E, Bertossi M, Roncali L. Glial cells and blood-brain barrier in the human cerebral cortex. Ital J Anat Embryol 1995; 100: (Suppl. 1): 177-184.
51. Riquelme G. Review: placental syncytiotrophoblast membranes-domains, subdomains and microdomains. Placenta 2011; 32: (Suppl. 2): S196-202.